GLP-1 receptor agonists demonstrate measurable reductions in hepatic steatosis, inflammation, and fibrosis biomarkers in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Dual-action medications like tirzepatide, targeting both GLP-1 and GIP receptors, show superior hepatic outcomes compared to single-target therapies. Emerging triple-agonist drugs such as retatrutide, which activate GLP-1, GIP, and glucagon receptors simultaneously, represent the next therapeutic frontier with early data suggesting potent liver-protective effects. This therapeutic approach addresses a critical gap in MASLD treatment, where no approved pharmacological interventions currently exist despite the condition affecting millions in industrialized nations. The liver benefits appear to stem from these drugs' ability to improve insulin sensitivity and promote weight loss, tackling the metabolic dysfunction at MASLD's core. However, the hepatoprotective mechanism may extend beyond metabolic improvements, potentially offering direct anti-inflammatory and anti-fibrotic effects. While promising, current evidence remains preliminary, and long-term liver outcomes require validation through dedicated hepatology trials rather than extrapolation from diabetes and obesity studies.